The Northern Institute of Cancer Research is the focus of research excellence in cancer studies at Newcastle University. Its mission is to use molecular genetic information derived from human cancers to identify novel therapeutic targets and develop drugs that exploit these novel targets. In the most recent, Research Assessment Excercise (REA 2009), 75% of the research was classed as internationally excellent, and another 15% as world leading.
There are strong links between clinical staff, both ward and laboratory based, and basic scientists. This enables a small and rapid translation of research results into clinical practice and has permitted the development of new drugs from ‘bench to bedside’. The Institute’s mission is to use molecular genetic information derived from human cancers to identify novel therapeutic targets and develop drugs that exploit these novel targets.
The Institute of Neuroscience brings together one of the UK’s largest groups of neuroscientists, with over 100 academic and clinical researchers. Exploitation of this translational environment is delivering new treatments for patient benefit and novel applications of the principles of neural systems. Research areas currently contributing to their commercialisation pipeline and IP portfolio include:
CARU provides an ideal high-quality environment for phase II – IV clinical studies in older patients. The primary aim is to facilitate the development of early assessment and intervention strategies targeted at age-associated degenerative conditions. Situated on the Newcastle General Hospital site, the unit is linked to the Magnetic Resonance Imaging (MRI) Centre and adjacent to the Positron Emission Tomography (PET) facility.
Members of the Diabetes Research Group at Newcastle University are also practicing diabetes clinicians in the NHS Newcastle Diabetes Centre. The NHS Newcastle Diabetes Centre can organise efficient clinical trials with partner organisations, with access to a large pool of well characterised patients.